{"id":49685,"date":"2022-06-21T12:00:00","date_gmt":"2022-06-21T17:00:00","guid":{"rendered":"https:\/\/www.tradestation.io\/insights\/?p=49685"},"modified":"2022-06-23T09:38:08","modified_gmt":"2022-06-23T14:38:08","slug":"united-therapeutics-technical-analysis-bullish","status":"publish","type":"post","link":"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/","title":{"rendered":"Chart of the Day: This Drug Developer Rallied and Now It’s Pulled Back"},"content":{"rendered":"\n
United Therapeutics spent more than a year consolidating around its 2015 highs. Now the biotech may be attempting a breakout.<\/p>\n\n\n\n
Notice the surge to new all-time highs late last month. The rally followed news that the Food & Drug Administration approved its Tyvaso DPI hypertension drug for two applications. (There were worries of a narrower approval.)<\/p>\n\n\n\n
UTHR paused for about three weeks and pulled back toward $215. That level is …<\/p>\n\n\n\n
For more, please\u00a0click\u00a0here\u00a0<\/a>to view the related idea and chart analysis on\u00a0TradingView<\/a>.<\/em><\/p>\n\n\n\n